Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects
HY Estupiñán, A Berglöf, R Zain… - Frontiers in cell and …, 2021 - frontiersin.org
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
Chronic lymphocytic leukemia
N Chiorazzi, KR Rai, M Ferrarini - New England Journal of …, 2005 - Mass Medical Soc
Our concept of the pathogenesis of chronic lymphocytic leukemia has undergone
remarkable changes during the past decade. This review addresses the latest ideas …
remarkable changes during the past decade. This review addresses the latest ideas …
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
RR Furman, JP Sharman, SE Coutre… - … England Journal of …, 2014 - Mass Medical Soc
Background Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically
significant coexisting medical conditions are less able to undergo standard chemotherapy …
significant coexisting medical conditions are less able to undergo standard chemotherapy …
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
Background Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors …
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors …
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
JC Byrd, RR Furman, SE Coutre, IW Flinn… - … England Journal of …, 2013 - Mass Medical Soc
Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell …
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell …
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
BJ Lannutti, SA Meadows, SEM Herman… - Blood, The Journal …, 2011 - ashpublications.org
Abstract Phosphatidylinositol-3-kinase p110δ serves as a central integration point for
signaling from cell surface receptors known to promote malignant B-cell proliferation and …
signaling from cell surface receptors known to promote malignant B-cell proliferation and …
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
JA Woyach, K Smucker, LL Smith… - Blood, The Journal …, 2014 - ashpublications.org
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has outstanding activity in patients with
chronic lymphocytic leukemia. Most patients experience lymphocytosis, representing …
chronic lymphocytic leukemia. Most patients experience lymphocytosis, representing …
Ras and Rap1: A tale of two GTPases
S Shah, EJ Brock, K Ji, RR Mattingly - Seminars in cancer biology, 2019 - Elsevier
Ras oncoproteins play pivotal roles in both the development and maintenance of many
tumor types. Unfortunately, these proteins are difficult to directly target using traditional …
tumor types. Unfortunately, these proteins are difficult to directly target using traditional …
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
JA Burger, MP Quiroga, E Hartmann… - Blood, The Journal …, 2009 - ashpublications.org
In lymphatic tissues, chronic lymphocytic leukemia (CLL) cells are interspersed with CD68+
nurselike cells (NLCs), T cells, and other stromal cells that constitute the leukemia …
nurselike cells (NLCs), T cells, and other stromal cells that constitute the leukemia …
B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor
N Chiorazzi, M Ferrarini - Annual review of immunology, 2003 - annualreviews.org
B cell chronic lymphocytic leukemia (B-CLL) is an accumulative disease of slowly
proliferating CD5+ B lymphocytes that develops in the aging population. Whereas some …
proliferating CD5+ B lymphocytes that develops in the aging population. Whereas some …